Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celldex Therapeutics (CLDX) EBIT (2016 - 2025)

Celldex Therapeutics has reported EBIT over the past 16 years, most recently at -$87.2 million for Q4 2025.

  • Quarterly results put EBIT at -$87.2 million for Q4 2025, down 55.56% from a year ago — trailing twelve months through Dec 2025 was -$287.4 million (down 47.31% YoY), and the annual figure for FY2025 was -$287.4 million, down 47.31%.
  • EBIT for Q4 2025 was -$87.2 million at Celldex Therapeutics, down from -$73.6 million in the prior quarter.
  • Over the last five years, EBIT for CLDX hit a ceiling of $36.0 million in Q4 2021 and a floor of -$87.2 million in Q4 2025.
  • Median EBIT over the past 5 years was -$38.5 million (2022), compared with a mean of -$38.4 million.
  • Biggest five-year swings in EBIT: skyrocketed 245.47% in 2021 and later tumbled 177.36% in 2022.
  • Celldex Therapeutics' EBIT stood at $36.0 million in 2021, then tumbled by 177.36% to -$27.9 million in 2022, then plummeted by 70.8% to -$47.6 million in 2023, then fell by 17.64% to -$56.0 million in 2024, then crashed by 55.56% to -$87.2 million in 2025.
  • The last three reported values for EBIT were -$87.2 million (Q4 2025), -$73.6 million (Q3 2025), and -$63.9 million (Q2 2025) per Business Quant data.